BlueWater Angels among state’s most enviable investors

Crain’s Detroit Business

Allergan prepares to expand Waco facility after delays

Waco Tribune-Herald

Tech Coast Angels Invested $14.1 Million into 55 Companies and Completed Six Exits in 2016

For PR Web, click here

During its 20th Year, Angel Network also Launched Angel Syndication Network to Share Deals with over 20 Other Angel Groups 

IRVINE, Calif. – April 25, 2017 – Tech Coast Angels (TCA) invested $14.1 million in a total of 55 companies in a diverse mix of industries in 2016. TCA’s total investment for the year was its fourth highest since the network’s inception in 1997, and its two largest deals in 2016 were Echo Labs and Movocash – each at over $1 million from TCA. TCA had six exits including five acquisitions (Retrosense Therapeutics, WeGoLook, Clearcare, Hipmunk, and HitFix) and one optional exit (grandPad) upon receiving strategic investment from Acer. This brings the total exits to 68 in the angel network’s history.

Ninety-one percent (91%) of the deals were seed or Series A rounds. Sixty-two percent (62%) of the companies in which TCA invested were initial investments by TCA, up from 35% in 2015. The investment increase in new and early stage companies reflected a wide berth of opportunities in 2016, however the report cautions that such investment activity may be similar to “experiencing an Indian Summer,” as this cycle seems to be drawing to a close.

These investments were across a broad range of industries, but the largest investments in dollars were in life sciences (35%), internet/apps (20%), software (15%) and financial services (16%).

“Although the year started slowly for investments, TCA finished strong in 2016.   Additionally, we started a new syndication network to build better deals with great companies regardless of geography,” said Jeff Draa, 2017 Chairman of Tech Coast Angels. “While the diverse experience of our over 300 members helps us as a network to invest with confidence in a wide range of industries, the amount of solid expertise and knowledge also greatly benefits the companies in which we invest, guide and mentor. Together, that formula has helped us achieve results in liquidity events that surpass the averages for other angel groups.”

TCA also participated, along with CommonAngels from Boston, in research that was published in a joint study by Harvard Business School and MIT last calendar year, which may be the first quantitative analysis showing that companies receiving angel funding achieve greater success in many areas (including employees, survival, patents granted, etc.) than companies who did not receive angel funding.

Access TCA’s full 2016 year-end report for more details. The report includes a summarization of 2016, the investment outlook for 2017, the list of companies added to our portfolio, and various infographics.

 

Retrosense Therapeutics: Looking beyond Traverse City’s tourism: Northern Michigan angel fund aims to broaden economic base, create year-round jobs

Crain’s Detroit Business

Retrosense Therapeutics: Life sciences sector is heartbeat of Michigan innovation

click here

Retrosense Therapeutics: Tech innovators honored at Michigan Venture Capital Association awards dinner

click here

Retrosense Therapeutics: What Allergan Is Buying and Shedding to Gain a Better Position

click here

RetroSense to be honored at TechTown awards program for $60 million sale

click here

The RetroSense Story: A Life Science Journey to Success

click here

Retrosense Therapeutics: WSU research leads to algae treatment for blindness

click here

With small RetroSense deal, Allergan hoping for big win

click here

Allergan seizes visionary Optogenetic Therapy from US Startup Retrosense Therapeutics

click here

Allergan buys gene therapy company, RetroSense Therapeutics

click here

Allergan acquires RetroSense Therapeutics

click here

Allergan Acquires RetroSense Therapeutics

click here

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline

click here

BRIEF-Allergan acquires gene therapy company Retrosense Therapeutics

click here

Allergan (AGN) Acquires RetroSense Therapeutics

click here

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline

click here

Allergan snaps up gene therapy startup Retrosense Therapeutics to restore vision in rare disease patients

click here

RetroSense Therapeutics Secures Exclusive Worldwide Rights to ReaChR Optogene from the University of California San Diego

click here

RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics

click here

RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics

click here

RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics

click here

RetroSense Therapeutics has been named one of the nation’s 50 smartest companies by the MIT Technology Review

click here

RetroSense Therapeutics Tech magazine ranks Wayne State spinoff as 37th smartest company in world

click here

RetroSense Therapeutics Selected as one of MIT Technology Review’s 50 Smartest Companies of 2016

click here

RetroSense Therapeutics Selected as one of MIT Technology Review’s 50 Smartest Companies of 2016

click here

RetroSense Therapeutics Selected as a Red Herring Top 100 North America Winner

click here

Light-controlled genes and neurons poised for clinical trials

click here

RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences

click here

Tech Coast Angels Invested Best Ever $16.37 Million in 2014

Southern California Angel Network Surpasses Previous Records for Both Investments and Activity

IRVINE, Calif. January 29, 2015 Tech Coast Angels (TCA) invested a total of $16,373,337 in 61 total deals in Calendar Year 2014. The angel network announced that 2014 was the most active year since the networks inception in 1997 for number of deals funded, and capital raised was also the largest ever. TCAs five networks throughout Southern California invested in a variety of industries last year, including consumer goods, healthcare, biotechnology, HIPAA-compliant data storage, social networking, organic agriculture, and automobile technology.In 1H 2014, TCA investments totaled $6,321,874 in 27 total deals. 2H 2014 saw a nearly 60% increase in the amount of total investment from the first half of the year, with $10,051,463 in 34 total deals. Compared to 2013, the angel network increased its total investment portfolio by nearly 12%, from $14,639,612 million in 2013 to $16,373,337 in 2014.After four successful exits in 2013 (Cognition Technologies, Green Dot, Lend Amend and Trius Therapeutics), 2014 brought five more positive exits with AIRSIS, Allylix, Bluebeam Software, Hookit (formerly Loopd Networks), and Mindbody Software. TCAs portfolio of new deals for 2014 include: Aggregage, Apeel Sciences, Ascendant Spirits, Beacon Healthcare, Edufii, Fusion Brake, GoBookIt, ImmunoGum, iPourIt, LeaseLock, Neural Analytics, Parcel Pending, Perfectna, Portfolium, Respiratory Motion, RetroSense Therapeutics, Ring Router, Schlep & Fetch, Soma Bar, Spine Innovation, The Influential Network, TrueVault, Unlicensed Chimp Technology, and WeGoLook. “We are excited by the quality and unique breadth and scope of these great, young, mostly Southern Californian companies that we can support through our experience and capital, said Michael Green, TCA incoming chairman. “We look forward to continuing to find, hone and cultivate the many outstanding early-stage companies in our community in 2015.